Edwards Lifesciences Corporation EW | NYSE
Company Overview:
10 Year Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
EW Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for EW
Based on past 10-year performance, here are EW growth metrics:
Share price CAGR of +13.49%
Dividend CAGR of +0%
Using EW CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| EW (DRIP) | EW - No DRIP | |
|---|---|---|
| Current Price | $75.18 | $75.18 |
| Start Shares | 133.01 | 133.01 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 133.01 | 133.01 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $234.90 | $75.18 |
| Total Dividends | $0 | $0 |
| Final Value | $31,246 | $10,000 |
NOTE: Above numbers are our estimate based on EW's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Edwards Lifesciences Corporation (EW) had its IPO on 2000-03-27, and is trader on NYSE stock exchange.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW website: https://www.edwards.com
